12 / 160
564
Conclusión
El EB sin complicaciones debe estar sujeto a seguimiento, en
donde la aparición de displasia determina la utilización de
terapia principalmente ablativa. La presencia de neoplasia
maligna focal superficial requiere de la resección de la lesión
para su adecuado estudio histopatológico. En estos casos el
tratamiento del EB residual es necesario. A pesar del éxito de
estas terapias, los pacientes deben ser seguidos endoscópica-
mente en forma permanente, por el riesgo de reaparición de su
enfermedad.
REFERENCIAS BIBLIOGRáFICAS
1.
Rex D, Cummings O, Shaw M, Cumings M, Wong R, Vasudeva R, et
al. Screening for Barrett’s esophagus in colonoscopy patients with
and without heartburn. Gastroenterology. 2003; 125:1670-
1677.
2. Burke ZD, Tosh D. Barrett’s metaplasia as a paradigm for
understanding the development of cancer. Current Opinion in
Genetics & Development. 2012; 22: 494-499.
3. Quante M, Bhagat G, Abrams J, Marache F, Good P, Lee MD, et
al. Bile acid and inflammation activate gastric cardia stem cells
in a mouse model of Barrett-like metaplasia. Cancer Cell. 2012;
21:36-51.
4. Wang X, Ouyang H, Yamamoto Y, Kumar PA, Wei TS, Dagher R,
et al. Residual embryonic cells as precursors of a Barrett’s-like
metaplasia. Cell. 2011; 145:1023-1035.
5. Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya
A, Sampliner RE. Medication usage and the risk of neoplasia in
patients with Barrett’s esophagus. Clin Gastroenterol Hepatol.
2009; 7: 1299-1304.
6. Sharma P, Morales TG, Sampliner RE. Short segment Barrett’s
esophagus. The need for standardization of the definition and of
endoscopic criteria. Am J Gastroenterol. 1998; 93: 1033-1036.
7. Sharma P, Dent J, Armstrong D, Bergman JJ, Gossner L, Hoshihara
Y, et al. The development and validation of an endoscopic
grading system for Barrett’s esophagus: the Prague C & M criteria.
Gastroenterology. 2006; 131: 1392–1399.
8. The Paris endoscopic classification of superficial neoplastic
lesions: esophagus, stomach, and colon: November 30 to
December 1, 2002. Gastrointest Endosc. 2003;58:S3-43.
9. Wolfsen HC. Endoluminal Therapy for Barrett’s Esophagus.
Gastrointestinal Endoscopy Clinics of North America. 2007; 17:
59-82.
10. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there
publication bias in the reporting of cancer risk in Barrett’s
esophagus?. Gastroenterology. 2000; 119: 333-338.
11. Pohl H, Sirovich B, Welch HG. Esophageal adenocarcinoma
incidence: are we reaching the peak? Cancer Epidemiol
Biomarkers Prev. 2010; 19: 1468-70. (Erratum in Cancer
Epidemiol Biomarkers Prev. 2010 Sep;19(9):2416).
12. Thrift AP, Whiteman DC. The incidence of esophageal
adenocarcinoma continues to rise: analysis of period and birth
cohort effects on recent trends. Ann Oncol. 2012; 23:3155-
3162.
13. Anaparthy R, Gaddam S, Kanakadandi V, Alson BR, Gupta
N, Higbee AD, et al. Association between length of Barrett’s
esophagus and risk of high- grade dysplasia or adenocarcinoma
in patients without dysplasia. Clinical Gastroenterology and
Hepatology. 2013 November; 11(11):1430-1436.
14. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures
effective in patients with gastroesophageal reflux disease?
An evidence based approach. Arch Intern Med. 2006; 166:
965-971.
15. Ness-Jensen E, Lindam A, Lagergren J, Hyeem K. Weight loss
and reduction in gastroesophageal reflux. A prospective
populationbased cohort study: the HUNT study. Am J
Gastroenterol. 2013; 108: 376-382.
16. Aslam M, Slaughter JC, Goutte M, Garrett CG, Hagaman D,
Vaezi MF. Nonlinear relationship between body mass index and
esophageal acid exposure in the extraesophageal manifestations
of reflux. Clinical Gastroenterology and Hepatology. 2012
August; 10(8): 874-878.
17. Spechler SJ, Fitzgerald RC, Prasad GA, Wang KK. History,
molecular mechanisms, and endoscopic treatment of Barrett’s
esophagus. Gastroenterology. 2010; 138: 854- 869.
18. Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK,
Fleischer DE, et al. Durability of radiofrequency ablation in
Barrett’s esophagus with dysplasia. Gastroenterology. 2011;
141(2): 460-468.
19. Semlitsch T, Jeitler K, Schoefl R, et al. A systematic review of the
evidence for radiofrequency ablation for Barrett’s esophagus.
Surg Endosc 2010;24(12): 2935-2943.
20. Gaddam S, Wani S. Endoscopic Therapy of Barrett Esophagus.
Gastrointest Endoscopy Clin N Am 2013; 23:1-6.
21. Phoa KN, Van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ,
Ragunath K. Radiofrequency Ablation vs Endoscopic Surveillance
for Patients With Barrett Esophagus and Low-Grade Dysplasia A
Randomized Clinical Trial. JAMA. 2014; 311(12): 1209-1217.
22. Gatenby P, Soon Y. Barrett’s oesophagus: Evidence from the
current meta-analyses. World J Gastrointest Pathophysiol.
2014;15: 178-187.
Los autores declaran no tener conflictos de interés, en relación a este artículo.
[REV. MED. CLIN. CONDES - 2015; 26(5) 557-564]